Purpose This single arm, phase II study aims to evaluate the role of epidermal growth factor
receptor–tyrosine-kinase inhibitor erlotinib as maintenance therapy following concurrent …

7537 Background: Combination of platinum-based chemotherapy and radiotherapy is the
standard treatment for p with unresectable stage III NSCLC, but considering the high rates of …

18501 Background: Based on recent studies, concurrent chemo-radiotherapy could be
considered the standard treatment of stage III NSCLC pts without malignant effusions …

Introduction This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib
administered with two standard chemoradiotherapy regimens for non-small cell lung cancer …

Purpose Although many studies have confirmed the synergic effects of combining
chemotherapy (CT) and radiotherapy (RT), clinical data evaluating safety and efficacy of …

Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …

Purpose To test, in a single-arm, prospective, phase 2 trial, whether adding the epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to concurrent …

Background The downstream signaling pathways of the epidermal growth factor receptor
might influence radiation resistance. Data from preclinical work support the hypothesis that …

Purpose Concurrent chemoradiotherapy (CCRT) is the standard care for stage III non-small
cell lung cancer (NSCLC) patients; however, a more effective regimen is needed to improve …

8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …